Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Randomized Experiments01:13

Randomized Experiments

9.1K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
9.1K
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

336
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
336
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

305
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
305
Censoring Survival Data01:09

Censoring Survival Data

609
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
609
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

462
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
462
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

658
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
658

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

MVA-BN monkeypox vaccine safety in a clinical trial in the Democratic Republic of the Congo.

NPJ vaccines·2026
Same author

Assessing Open-world Foundation Models for Zero-shot Skin Segmentation in Clinical Dermatological Photographs.

Proceedings of SPIE--the International Society for Optical Engineering·2026
Same author

Reflections on FDA Draft Guidance on Bayesian Methods in Trials-Protecting Scientific Integrity and Evidentiary Standards.

JAMA·2026
Same author

Event-driven planning of two-armed trials with a binary endpoint.

Clinical trials (London, England)·2026
Same author

Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.

Science translational medicine·2026
Same author

Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.

Lancet (London, England)·2025
Same journal

A statistical evaluation of decision-making methods and the efficiency of Bayesian multi-arm multi-stage trials.

Clinical trials (London, England)·2026
Same journal

Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Clinical trials (London, England)·2026
Same journal

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same journal

Trial informed consent forms, the Declaration of Helsinki and the SPIRIT 2025 statement.

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Morning panel discussion).

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Afternoon panel discussion).

Clinical trials (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Feb 26, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

不完全な中間エンドポイントを用いた応答適応ランダム化

Yousra Kherabi1,2,3, Michael A Proschan4, Lori E Dodd3,4

  • 1Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Clinical trials (London, England)
|February 25, 2026
PubMed
まとめ
この要約は機械生成です。

結核における培養転換のような不完全な中間エンドポイントを用いた応答適応ランダム化は、患者を最良の治療法に確実に割り当てられない可能性がある。患者割り当ての効果にはエンドポイントの精度が重要である。

キーワード:
結核適応デザイン臨床試験中間エンドポイント応答適応ランダム化

さらに関連する動画

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.6K

関連する実験動画

Last Updated: Feb 26, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.6K

科学分野:

  • 臨床試験方法論
  • 生物統計学
  • 感染症研究
  • Clinical Trials Methodology; Biostatistics; Infectious Disease Research

背景:

  • 応答適応ランダム化は、特に長期の主要アウトカムを伴う場合、議論の的となっている。
  • 中間エンドポイントは、長期のフォローアップを必要とする試験でランダム化を更新するために使用される。
  • 結核試験は、不完全なデータを用いた適応デザインの評価の文脈として役立つ。
  • Response-adaptive randomization is debated, especially with long-term primary outcomes.; Intermediate endpoints are used to update randomization in trials requiring extended follow-up.; Tuberculosis trials serve as the context for evaluating adaptive designs with imperfect data.

研究 の 目的:

  • 不完全な中間エンドポイントを利用した応答適応ランダム化の影響を評価すること。
  • 適応デザインが参加者を優れた治療アームに割り当てる効果を評価すること。
  • 中間エンドポイントの精度と時間トレンドが試験結果に与える影響を調査すること。
  • To assess the impact of response-adaptive randomization utilizing an imperfect intermediate endpoint.; To evaluate the effectiveness of adaptive designs in allocating participants to superior treatment arms.; To examine the influence of intermediate endpoint accuracy and time-trends on trial outcomes.

主な方法:

  • 3アームの優越性試験の応答適応ランダム化デザインをシミュレートした。
  • 73週間の主要アウトカム（治療成功）の中間エンドポイントとして8週間の培養転換を使用した。
  • 感度、特異度、および真の治療効果を変化させて、適応ランダム化のパフォーマンスと第一種の過誤を分析した。
  • Simulated a response-adaptive randomization design for a three-arm superiority trial.; Used culture conversion at 8 weeks as an intermediate endpoint for a 73-week primary outcome (treatment success).; Varied sensitivity, specificity, and true treatment efficacy to analyze adaptive randomization performance and type I error.

主要な成果:

  • 完全な中間エンドポイントの精度であっても、適応ランダム化は一貫してより良いアームを支持しなかった。中間エンドポイントの精度が低いと、優れたアームにより多くの患者を割り当てるという目標が大幅に低下した。時間トレンドは第一種の過誤を増加させた。層別化はこれを修正したが、統計的検出力を低下させた。
  • Even with perfect intermediate endpoint accuracy, adaptive randomization did not consistently favor the better arm.; Lower accuracy of the intermediate endpoint significantly reduced the goal of allocating more patients to the superior arm.; Time-trends increased type I error; stratification corrected this but reduced statistical power.

結論:

  • 応答適応ランダム化は、複数のレジメンを効率的に評価するために魅力的である。
  • しかし、それは非常に正確な中間エンドポイントを必要とするが、それは信頼できる患者割り当てを保証するものではない。
  • 不完全な中間エンドポイントでは、応答適応ランダム化の信頼性は疑問視される。
  • Response-adaptive randomization is appealing for evaluating multiple regimens efficiently.; However, it necessitates highly accurate intermediate endpoints, which do not guarantee reliable patient allocation.; The trustworthiness of response-adaptive randomization is questionable with imperfect intermediate endpoints.